Kalb, Birgit
Meixner, Lara
Trendelenburg, Valérie
Unterleider, Nathalie
Dobbertin-Welsch, Josefine
Heller, Stephanie
Dölle-Bierke, Sabine
Roll, Stephanie
Lau, Susanne
Lee, Young-Ae
Fauchère, Florent
Braun, Julian
Babina, Magda
Altrichter, Sabine
Birkner, Till
Worm, Margitta
Beyer, Kirsten http://orcid.org/0000-0003-1859-0419
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (428046232)
Charité - Universitätsmedizin Berlin
Article History
Received: 22 January 2022
Accepted: 22 February 2022
First Online: 12 March 2022
Declarations
:
: The trial was approved by the Ethics Committee of Charité – Universitätsmedizin Berlin (REC reference EA2/032/19) on 03 March 2019 prior to the start of recruitment. Any substantial amendments to the protocol or to the consent materials must also be approved by the Ethics Committee of Charité – Universitätsmedizin Berlin before implementation.All parents give their full consent before their children are enrolled into the trial. The written informed consent must be given by both the mother and father, or the legal representatives. The informed consent form must be revised whenever important new safety information is available, whenever the protocol is amended leading to changes in study procedures relevant for the patient, and/or whenever any new information becomes available that may affect participation in the trial.
: Not applicable.
: VT received speaker’s fees from Nutricia/Danone. KB reports grants/research supports from Aimmune, Danone/Nutricia/Milupa, DBV, Hipp, Hycor, Infectopharm, and honoraria or consultation fees from Aimmune, Bencard, Danone/Nutricia/Milupa, DBV, Hipp, Hycor, Infectopharm, Jenapharma, Mylan/Meda, Nestle, Novartis, ThermoFisher, outside of the submitted work. MW declares the receipt of honoraria or consultation fees by the following companies: ALK-Abelló Arzneimittel GmbH, Mylan Germany GmbH, Leo Pharma GmbH, Sanofi-Aventis Deutschland GmbH, Regeneron Pharmaceuticals, DBV Technologies S.A, Stallergenes GmbH, HAL Allergie GmbH, Allergopharma GmbH & Co.KG, Bencard Allergie GmbH, Aimmune Therapeutics UK Limited, Actelion Pharmaceuticals Deutschland GmbH, Novartis AG, Biotest AG., AbbVie Deutschland GmbH & Co. KG and Lilly Deutschland GmbH. All other authors report that they have no competing interests.